Ospedale E.Muscatello

The research at Ospedale E.Muscatello targets atrial fibrillation patients who cannot use oral anticoagulants, aiming to reduce the incidence of stroke and systemic embolism.

• Evaluation of novel antibody therapies for clot prevention
• Assessment of major bleeding risk
• Comparison with placebo in high‑risk populations

The site’s two investigators collaborate to improve cardiovascular outcomes for the local community and beyond.

Studies examine multiple sclerosis, specifically the non‑relapsing secondary progressive form, testing the ability of frexalimab to delay disability progression.

• Investigation of disease‑modifying antibody therapy
• Safety monitoring in adult participants
• Evaluation of long‑term functional outcomes

This trial highlights the hospital’s dedication to advancing treatments for neuro‑degenerative disorders across Europe.